Guggenheim analyst Debjit Chattopadhyay downgraded Intellia Therapeutics (NTLA) to Neutral from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations
- Intellia Therapeutics falls -46.3%
- Intellia Therapeutics price target lowered to $48 from $60 at Chardan
- Intellia Therapeutics: Buy Rating Affirmed Amid Phase 3 Trial Pause and Long-term Confidence